{"id":"mefloquine-and-dihydroartemisinin-piperaquine","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Neuropsychiatric effects (mefloquine component)"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Mefloquine is a quinoline antimalarial that accumulates in the parasite's food vacuole and prevents detoxification of heme, leading to parasite death. Dihydroartemisinin (the active metabolite of artemisinin) generates free radicals that damage parasite proteins and membranes, while piperaquine provides additional blood schizonticide activity. The combination targets different parasite pathways, reducing resistance development.","oneSentence":"This combination antimalarial works by disrupting parasite blood-stage development through multiple mechanisms: mefloquine inhibits heme polymerization in the parasite digestive vacuole, while dihydroartemisinin-piperaquine generates reactive oxygen species and inhibits parasite protein synthesis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:54:16.766Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Malaria treatment and prevention (Plasmodium falciparum and other species)"}]},"trialDetails":[{"nctId":"NCT01640587","phase":"NA","title":"Compare the Effectiveness Between Existing Treatment and New Treatment","status":"TERMINATED","sponsor":"University of Oxford","startDate":"2013-11","conditions":"P. Falciparum Malaria","enrollment":76},{"nctId":"NCT03355664","phase":"PHASE3","title":"Study to Compare the Triple ACT AL+AQ With the ACT AL in Cambodia and Vietnam","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2018-03-19","conditions":"Malaria, Falciparum","enrollment":310},{"nctId":"NCT05052502","phase":"NA","title":"Targeting High Risk Populations With Enhanced Reactive Focal Mass Drug Administration in Thailand","status":"UNKNOWN","sponsor":"University of California, San Francisco","startDate":"2020-11-01","conditions":"Plasmodium Falciparum Malaria, Plasmodium Vivax Malaria","enrollment":49118},{"nctId":"NCT01054248","phase":"PHASE3","title":"Randomised Trial of 3 Artemisinin Combination Therapy for Malaria in Pregnancy","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2010-02-16","conditions":"Malaria","enrollment":511},{"nctId":"NCT02653898","phase":"PHASE4","title":"Malaria Elimination Pilot Study in Military Forces in Cambodia","status":"UNKNOWN","sponsor":"Armed Forces Research Institute of Medical Sciences, Thailand","startDate":"2016-01","conditions":"Malaria, Parasitic Diseases","enrollment":1050},{"nctId":"NCT02612545","phase":"PHASE1","title":"Efficacy, Safety, and Tolerability of Dihydroartemisinin-piperaquine + Mefloquine Compared to Dihydroartemisinin-piperaquine or Artesunate-mefloquine in Patients With Uncomplicated Falciparum Malaria in Cambodia","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-11-20","conditions":"Acute Falciparum Malaria","enrollment":216},{"nctId":"NCT02453308","phase":"PHASE2, PHASE3","title":"A Study by the Tracking Resistance to Artemisinin Collaboration (TRAC)","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2015-08","conditions":"Malaria, Falciparum","enrollment":1110},{"nctId":"NCT02974348","phase":"PHASE3","title":"Antimalaria Drugs Susceptibility Testing for an Effective Management of Infected Patients in Sub-Sahara Africa","status":"COMPLETED","sponsor":"University of Bamenda","startDate":"2013-01","conditions":"Drug Resistant Malaria Due to Plasmodium Falciparum","enrollment":300},{"nctId":"NCT02792816","phase":"","title":"Molecular Surveillance of Artemisinin Resistance Malaria in Myanmar","status":"COMPLETED","sponsor":"Department of Medical Research, Lower Myanmar","startDate":"2009-06","conditions":"Drug Resistance, Plasmodium Falciparum Malaria","enrollment":550},{"nctId":"NCT00852423","phase":"PHASE3","title":"Safe and Efficacious Artemisinin-based Combination Treatments for African Pregnant Women With Malaria","status":"COMPLETED","sponsor":"Institute of Tropical Medicine, Belgium","startDate":"2010-06","conditions":"Malaria in Pregnancy","enrollment":3428},{"nctId":"NCT02324738","phase":"PHASE4","title":"Pharmacokinetic and Pharmacodynamic Study of Mefloquine and Dihydroartemisinin-Piperaquine in Healthy Subjects","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2015-01","conditions":"Healthy","enrollment":16},{"nctId":"NCT00373607","phase":"PHASE3","title":"Efficacy and Safety of Dihydroartemisinin/Piperaquine (Artekin®) for the Treatment of Uncomplicated Malaria in Peru","status":"COMPLETED","sponsor":"Institute of Tropical Medicine, Belgium","startDate":"2003-07","conditions":"Malaria","enrollment":522},{"nctId":"NCT00902811","phase":"PHASE4","title":"Effectiveness of Artemisinin Combination Regimens in Falciparum Malaria","status":"UNKNOWN","sponsor":"Medecins Sans Frontieres, Netherlands","startDate":"2008-12","conditions":"Uncomplicated Falciparum Malaria","enrollment":600}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":102,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Mefloquine and Dihydroartemisinin-piperaquine","genericName":"Mefloquine and Dihydroartemisinin-piperaquine","companyName":"University of Oxford","companyId":"university-of-oxford","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination antimalarial works by disrupting parasite blood-stage development through multiple mechanisms: mefloquine inhibits heme polymerization in the parasite digestive vacuole, while dihydroartemisinin-piperaquine generates reactive oxygen species and inhibits parasite protein synthesis. Used for Malaria treatment and prevention (Plasmodium falciparum and other species).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}